Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus HYDROCORTISONE VALERATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus HYDROCORTISONE VALERATE.
CORTIFOAM vs HYDROCORTISONE VALERATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
Apply a thin film to affected area twice daily. Topical use only.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Terminal elimination half-life is approximately 2-3 hours for the parent drug; 18-36 hours for the active metabolites (clinical context: duration of action is prolonged due to local tissue retention and metabolite activity)
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Renal (approximately 80% as metabolites, <1% unchanged), fecal/biliary (approximately 20% as metabolites)
Category C
Category D/X
Corticosteroid
Corticosteroid